GetTopicDetailResponse(id=7139264699f, topicName=佐劑, introduction=佐劑, content=null, image=null, comments=1, allHits=1776, url=https://h5.medsci.cn/topic?id=26469, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=6423, tagList=[TagDto(tagId=6423, tagName=佐劑)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2231395, encodeId=e77a223139581, content=<a href='/topic/show?id=7139264699f' target=_blank style='color:#2F92EE;'>#佐劑#</a> <a href='/topic/show?id=c4cc11024228' target=_blank style='color:#2F92EE;'>#免疫因素#</a>, objectTitle=與疫苗反應(yīng)地域差異相關(guān)的免疫因素, objectType=article, longId=847087, objectId=966984e087d0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240714/1720959550643_5579292.png, objectUrl=/article/show_article.do?id=966984e087d0, replyNumber=0, likeNumber=108, createdTime=2024-10-17, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=966984e087d0, moduleTitle=與疫苗反應(yīng)地域差異相關(guān)的免疫因素, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=966984e087d0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1003171, encodeId=969f10031e1c2, content=國(guó)產(chǎn)滅活疫苗，最強(qiáng)的是康泰，其中和抗體滴度與<a href='/topic/show?id=43c112234fc' target=_blank style='color:#2F92EE;'>#mRNA疫苗#</a>相比美！可能是<a href='/topic/show?id=7139264699f' target=_blank style='color:#2F92EE;'>#佐劑#</a>水平比較高。智飛疫苗技術(shù)是重組蛋白，但是佐劑水平欠缺，因此，與國(guó)外的<a href='/topic/show?id=bbce1043e9fe' target=_blank style='color:#2F92EE;'>#重組蛋白疫苗#</a>相比，仍然有差距, objectTitle=EClinicalMedicine：國(guó)藥新冠疫苗接種第3劑，中和抗體能達(dá)到什么水平？, objectType=article, longId=214945, objectId=42612149451a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20210719/95079a4785a44c71b7c56e0d79e10b5d.jpg, objectUrl=/article/show_article.do?id=42612149451a, replyNumber=0, likeNumber=181, createdTime=2021-07-27, rootId=0, userName=小小醫(yī)者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42612149451a, moduleTitle=EClinicalMedicine：國(guó)藥新冠疫苗接種第3劑，中和抗體能達(dá)到什么水平？, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=42612149451a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
